To evaluate the efficacy and safety profile of Rosuvastatin, Simvastatin and Atorvastatin in newly diagnosed type 2 diabetic patients with dyslipidaemia
Keywords:
rosuvastatin, simvastatin, atorvastatin, type 2 diabetic patients, dyslipidaemiaAbstract
Dyslipidemia is one of the major risk factors for cardiovascular disease in diabetes mellitus. The lipid changes associated with diabetes mellitus are attributed to increased free fatty acid flux secondary to insulin resistance. This is prospective, comparative, open label, randomized and parallel group. The subjects enrolled for this study were selected from the Out-Patient Department of Medicine collaboration with Department of Pharmacology, Tertiary care teaching hospital over a period of month. Newly diagnosed 90 cases of patients of Type II Diabetes Mellitus well controlled on oral hypoglycemic drugs were randomly divided into 3 groups of 30 each. Group A was received Rosuvastain 10 mg O.D for 3 months, Group B: Simvastatin 10 mg O.D and Group C was received Atrovastatin 10 mg O.D. In Group ‘A’ the mean difference of Total Cholesterol between baseline versus after 6 months was 82.37 mg/dl, 64.92 mg/dl and 52.23 mg/dl in Group B and Group C respectively. The mean difference of Triglycerides between baseline versus after 6 months was 65.04 mg/dl in Group A, 39.99 mg/dl in Group B and 37.04 mg/dl in Group C.
Downloads
References
Unnikrishnan R, Anjana RM, Mohan V. Diabetes mellitus and its complications in India. Nat Rev Endocrinol. 2016;12(6):357–370.
Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW, et al. American association of clinical endocrinologists' guidelines for management of Dyslipidemia and prevention of atherosclerosis. Endocr Pract 2012;18 Suppl 1:1-78.
Chen G, McAlister FA, Walker RL, Hemmelgarn BR, Campbell NR. Cardiovascular outcomes in framingham participants with diabetes: the importance of blood pressure. Hypertension. 2011 May;57(5):891-7.
Bobby D, Vinodha R. Dyslipidemia in type 2 diabetes mellitus – a major risk factor for cardiovascular morbidity. Int J Med Res Rev 2016;4(8):1387-1391.
Osuji C.U., Nzerem B.A., Dioka C.E. Metabolic syndrome in newly diagnosed type 2 diabetes mellitus using NCEP-ATPIII, the Nnewi experience. Niger J Clin Pract. 2012 Oct–Dec;15(4):475–480.
Jayarama N, Reddy M, Lakshmaiah V. Prevalence and pattern of dyslipidemia in type 2 diabetes mellitus patients in a rural tertiary care centre, southern India. Glob J Med Public Health 2012;1:24-8.
Mohan V, Sandeep S, Deepa R, Shah B, Varghese C. Epidemiology of type 2 diabetes: Indian scenario. Indian J Med Res. 2007;125:217-30.
Anjana RM, Pradeepa R, Deepa M, Datta M, Sudha V, Unnikrishnan R. ICMR–INDIAB Collaborative Study Group. Prevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance) in urban and rural India: Phase I results of the Indian Council of Medical Research India Diabetes (ICMR INDIAB) study. Diabetologia. 2011;54:3022-7.
Kengne A.P., Limen S.N., Sobngwi E. Metabolic syndrome in type 2 diabetes: comparative prevalence according to two sets of diagnostic criteria in sub-Saharan Africans. Diabetol Metab Syndr. 2012 May 31;4(1):22.
Selvin E, Coresh J, Golden SH, Boland LL, Brancati FL, Steffes MW; Atherosclerosis risk in communities study. Glycemic control, atherosclerosis, and risk factors for cardiovascular disease in individuals with diabetes: the atherosclerosis risk in communities study. Diabetes Care. 2005 Aug;28(8):1965-73.
Gavin JR 3rd. Reducing global cardiovascular risk in patients with type 2 diabetes mellitus. J Am Osteopath Assoc. 2008 May;108(5 Suppl 3):S14-9.
Marjani A., Shirafkan A. The metabolic syndrome in type 2 diabetic patients in Gorgan: according to NCEP ATPIII and IDF definitions. Diabetes Metabol Syndr: Clin Res Rev. 2011 Apr;5(4):207–210.
Janghorbani M., Amini M. Incidence of metabolic syndrome and its risk factors among type 2 diabetes clinic attenders in Isfahan, Iran. ISRN Endocrinol. 2012;2012:167318.
Gokcel A, Karakose H, Ertorer EM, Tanaci N, Tutuncu NB, Guvener N. Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. Diabetes Care. 2001 Nov;24(11):1957-60.
Taylor HA Jr, Akylbekova EL, Garrison RJ, Sarpong D, Joe J, Walker E, Wyatt SB, Steffes MW. Dyslipidemia and the treatment of lipid disorders in African Americans. Am J Med. 2009 May;122(5):454-63.
Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D, Hague W, Beller E, Arulchelvam M, Baker J, Tonkin A; LIPID Study Group. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care. 2003 Oct;26(10):2713-21.
Farmer JA. Diabetic dyslipidemia and atherosclerosis: Evidence from clinical trials. Curr Diab Rep. 2008;8:71-7.
Misra A, Pandey RM, Devi JR, Sharma R, Vikram NK, Khanna N. High prevalence of diabetes, obesity and dyslipidaemia in urban slum population in northern India. Int J Obes Relat Metab Disord. 2001;25:1722-9.
Masram SW, Bimanpalli MV, Ghangle, S. Study of lipid profile and glycated hemoglobin in Diabetes mellitus. Indian Medical Gazette. 2012;257-65.
Parikh RM, Joshi SR, Menon PS, Shash NS. Prevalence and Pattern of Diabetic Dyslipidemia in Indian type 2 Diabetic patients. Diabetes and Metabolic Syndrome. Clinical Research and Review. 2010;4(1):10-12.
Smith S, Lall AM. A Study on Lipid Profile Levels of Diabetics and Non-Diabetics Among Naini Region of Allahabad, India. Turk J Biochem. 2008;33(4):138-41.
Rani HS, Madhavi G, Rao VR, Sahay BK, Jyothy A. Risk factors for coronary heart disease in type II diabetes mellitus. Indian J Clin Biochem. 2005;20(2):75-80.
Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D. LIPID Study Group. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes care. 2003;26(10):2713-21.
Pandya H, Lakhani JD, Dadhania J, Trivedi A. The prevalence and pattern of dyslipidemia among type 2 diabetic patients at rural based hospital in Gujarat, India. J Clin Prac. 2012;22(12):36-44.
Samatha P, Venkateswarlu M, Siva Prabodh V. Lipid profile levels in type 2 diabetes mellitus from tribal population of Adilabad in Andhra Pradesh, India. J Clin Diagnostic Res. 2012;6(4):590-2.
Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabet Care. 2004;27:1496-504.
Mahato RV, Gyawali P, Raut PP, Regmi P, Singh PK, Pandey DR, et al. Association between glycaemic control and serum lipid profile in type 2 diabetic patients: glycated haemoglobin as a dual biomarker. Biomed Res. 2011;22(3):375-80.
Firdous S, Khan MZ. Comparison of patterns of lipid profile in type-2 diabetics and nonraised diabetics. Ann King Edward Med Coll. 2007;3(1):84-7.
Dixit AK, Dey R, Suresh A, Chaudhuri S, Panda AK, Mitra A, et al. The prevalence of dyslipidemia in patients with diabetes mellitus of ayurveda Hospital. J Diabet Metabol Disorders. 2014;13:58.
Uttra KM, Devrajani BR, Shah SZA, Devrajani T, Das T, Raza S, et al. Lipid Profile of Patients with Diabetes mellitus. World Appl Sci. 2011;J12(9):1382-4.
Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Health and treatment of diabetes mellitus. International Journal of Health Sciences, 5(1), i-v. https://doi.org/10.53730/ijhs.v5n1.2864
Mahardika, I. M. R., Suyasa, I. G. P. D., Kamaryati, N. P., & Wulandari, S. K. (2021). Health literacy is strongest determinant on self-monitoring blood glucose (SMBG) type 2 DM patients during COVID-19 pandemic at public health centre in Tabanan Regency. International Journal of Health & Medical Sciences, 4(3), 288-297. https://doi.org/10.31295/ijhms.v4n3.1752
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
